Drug Trial Radar · NCT07001319
Study of GS-3242 in Participants With HIV-1; Substudy-05
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
May 29, 2025
Primary completion
Mar 3, 2026
Study completion Apr 16, 2026
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jun 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.
Conditions
- HIV-1-infection
Interventions
GS-3242Drug
Administered orally
BVYDrug
Administered orally
Standard of CareDrug
Antiretroviral therapy, administered orally Non-NNRTIs, examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo DataTime frame: Baseline, Day 11
Locations
28 sites in 3 countries. Site status is shown where the registry gives one.
Franco Felizarta, MD
Bakersfield, California
Ruane Clinical Research Group, Inc
Los Angeles, California
Mills Clinical Research
Los Angeles, California
Quest Clinical Research
San Francisco, California
Washington Health Institute
Washington D.C., District of Columbia
Midland Florida Clinical Research Center, LLC
DeLand, Florida
AIDS Healthcare Foundation - Northpoint
Fort Lauderdale, Florida
Midway Immunology & Research Center, LLC
Ft. Pierce, Florida
BLISS Health
Orlando, Florida
Orlando Immunology Center, PA
Orlando, Florida
Triple O Research Institute, P.A.
West Palm Beach, Florida
Chatham County Health Department
Savannah, Georgia
Indiana University School of Medicine
Indianapolis, Indiana
Be Well Medical Center
Berkley, Michigan
KC CARE Health Center
Kansas City, Missouri
University of Cincinnati College of Medicine
Cincinnati, Ohio
Central Texas Clinical Research
Austin, Texas
Prism Health North Texas
Dallas, Texas
North Texas Infectious Diseases Consultant's, P.A.
Dallas, Texas
AXCES Research Group, LLC
El Paso, Texas
AXCES Research Group, LLC
Salt Lake City, Utah
ProcliniQ Investigación Clínica S.A. de C.V
Mexico City, Mexico
Institute of HIV Research and Innovation (IHRI)
Bangkok, Thailand
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Bangkok, Thailand
Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Thailand
Srinagarind Hospital, Faculty of Medicine, Khon Kaen University
Khon Kaen, Thailand
Bamrasnaradura Infectious Diseases Institute
Nonthaburi, Thailand
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),Thai Red Cross AIDS and Infectious Disease Research Center
Pathumwan, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.